This might explain the results from our study: 1) the expression of PD-L1 might be related to TIL-mediated antitumor inflammatory response, and rather than tumor immune escape; 2) the expression of PD-L1 varied in different molecular types of breast cancer; 3) the expression of PD-L1 were at the protein level rather than at the mRNA level. The gene discussed is CD274; the disease is breast cancer.